STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (“Applied DNA") (NASDAQ:APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics, announced that Dr. James Hayward, president & CEO, will participate in two upcoming investor conferences:
- 18th Annual B. Riley Institutional Investor Conference in Santa Monica on Wednesday, May 24 and Thursday, May 25. Dr. Hayward is scheduled to present on Wednesday, May 24 at 3:30pm PT and will host one-on-one meeting throughout the two days.
- 7th Annual LD Micro Invitational Conference in Los Angeles on Tuesday, June 6 and Wednesday, June 7. Dr. Hayward is scheduled to present on Tuesday, June 6 at 10:30am PT and will host one-on-one meeting throughout the two days.
Dr. Hayward’s presentation at each conference will be webcast through the Investor Relations section of the company's website at www.adnas.com.
About Applied DNA Sciences
Applied DNA Sciences makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainTTM” platform can be used to identify, tag, track, and trace products, to help assure authenticity, origin, traceability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track- and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.
Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017 and May 11, 2017, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.